TOMI Environmental Solutions is no longer being priced as a standalone disinfection franchise. The Frederick, Maryland vendor of SteraMist ionized hydrogen peroxide systems just posted a second-quarter rebound after a capital-spending drought, then signed a definitive reverse merger that would hand control of the public company to Carbonium Core. Carbonium is a development-stage nuclear-grade graphite producer. Legacy holders keep a thin residual claim if the deal closes on the stated terms. The operating print and the corporate-control print now pull in opposite directions.
Second-quarter sales more than doubled as custom chambers and handheld applicators returned. That is the first clean evidence the razor-and-blade model still works when hospitals and drug makers resume equipment budgets. Cash at mid-year was only $322,000, and management again flagged substantial doubt about continuing as a going concern. The merger contemplates Carbonium owners holding about ninety percent of the combined company after preferred conversion, plus a required $10 million financing. Nasdaq already determined the stock subject to delisting in May on bid-price and equity tests. A July reverse split and September note conversions try to repair the listing math without repairing the cash engine.
Gross margin stayed above sixty percent even as mix shifted toward equipment. Backlog and an advanced-stage pipeline give some second-half visibility against a full-year sales target of at least $12 million. The open question is which company investors actually own by year-end: a still-lossy SteraMist operator that finally grew, or a ten percent stub inside a renamed graphite developer that has not yet proven it can fund or list the combined vehicle.